Recordati Industria Chimica E Farmaceutica SpA

Recordati’s 114k‑share buy‑back boosts EPS and signals confidence, while emerging neuro‑endocrine therapies promise growth—under value‑based reimbursement, RWE, and AI‑driven care.

Recordati’s latest share‑buyback and VAZKEPA® partnership boost investor value and position the company for growth in Europe’s cardiovascular market.

Recordati’s 2025 results show a 12% rise from its rare‑disease division, driven by a successful US oncology launch and solid haematology sales, boosting revenue and EBITDA beyond industry averages.

Recordati’s 2025 earnings reveal double‑digit growth driven by rare‑disease drugs, an expanding endocrine therapy, and strong margins, positioning the company for continued 2026 revenue expansion and a bullish investor outlook.

Recordati’s 2025 earnings show robust revenue growth and soaring EBITDA, underpinned by value‑based pricing, operational efficiency and tech‑driven innovation—positioning it for strong 2027 gains and enhanced patient access.

Recordati’s 2025 results show 6% revenue growth and 15% EBITDA lift, driven by Specialty & Primary Care and a breakthrough Rare Diseases therapy, positioning the firm for 2027 gains.

Recordati’s 2025 earnings beat expectations with 8.3% revenue growth, a 19.4% operating margin, and a strong rare‑disease pipeline—outpacing rivals while maintaining ESG excellence.

Recordati’s shares lift modestly after 2025 earnings, as Barclays upgrades the company to equal‑weight amid its China exit, hinting at steady fundamentals but uncertain growth.

Recordati shares dip in Milan as pharma sector sells off—find out why and how investors can navigate short‑term volatility.

Recordati’s share‑buyback and governance strategy shows how a family‑owned pharma firm can boost shareholder value while maintaining market liquidity and professional oversight.